COMP <GO>
HLIO vs TMO // ENTERPRISE SCALE & MARKET CAP
Helios Technologies Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: HLIO 5
— TMO 7
▲ ENTERPRISE SCALE & MARKET CAP LEADER: TMO
LAST: $68.26 (+0.90%) • MKT CAP: $2.25B
market-cap
$2.25B
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
market-cap
$262.22B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HLIO VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HLIO | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 32.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.70% | 9.30% | -4.60 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 28.3x | 30.4x | -2.10 | HLIO | /valuation <GO> |
| Free Cash Flow Yield | 4.60% | 2.40% | +2.20 | HLIO | /fcf-yield <GO> |
| Operating Margin | 7.90% | 17.40% | -9.50 | TMO | /operating-margins <GO> |
| Net Profit Margin | 5.80% | 15.10% | -9.30 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 4.10% | 3.90% | +0.20 | HLIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.53% | 0.24% | +0.29 | HLIO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.73 | 4.50 | -0.77 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | HLIO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.5 | 62.9 | -22.35 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 43.2x | 36.3x | +6.90 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $2.25B | $262.22B | -$259.96B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HLIO REV | TMO REV | HLIO GROSS % | TMO GROSS % | HLIO FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $839.0M | $44.56B | 32.3% | — | $103.6M | $6.29B |
| FY 2024 | $805.9M | $42.88B | 31.3% | — | $95.1M | $7.27B |
| FY 2023 | $835.6M | $42.86B | — | — | $83.9M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HLIO // BETA —
TMO // BETA 0.94